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Abstract
Background: Colorectal cancer (CRC) is one of the most common cancer and the leading causes of cancer
mortality worldwide. The critical role of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor
(VEGF) are important in the cancer development.
Methods: The purpose of this study was to investigate the association of miR-199a expression in CRC and non-tumor
tissues as well as assessed the effect of miR-199a on biological behaviors including cell proliferation, apoptosis, migration
and invasion of CRC cells. The expression of miR-199a was distinctly decreased in colorectal cancer tissues compared
with non-neoplastic colorectal tissues.
Results: In this study, we found that miR-199a down-regulation was associated with the CRC and metastasis incidence.
Advanced study showed that miR-199a up-regulation would lead to decreased CRC proliferation, migration and invasion.
However, no significant association of miR-199a treatment and apoptosis rate and cell-cycle were detected in this study.
The detection for the mechanisms of miR-199a on the development of CRC showed that the anticarcinogenic effect of
miR-199a might be produced through HIF-1α/VEGF pathway.
Conclusion: It was found that miR-199a would reduce the proliferation, migration and invasion. However,
overexpression of miR-199a on the apoptosis rate and cell cycles showed no significant results. The potential
functionary mechanism of miR-199a might through HIF-1α/VEGF pathway.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
9806714131513041.
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Background
Colorectal cancer (CRC) is the third most common
cancer and one of the leading causes of cancer mortality
worldwide [1]. Despite considerable work on the
tumourigenesis and progression of CRC, however, the
detailed pathogenesis of this complex disease is poorly
understood by now. The importance of hypoxia-
inducible factor 1α (HIF-1α) in tumorigenesis is reported
by the finding that HIF-1α was a potential important key
regulatory factor in the development of CRC [2]. HIF-1α
is overexpressed in a variety of tumors including CRC
and the expression of HIF-α is often associated with
poor prognosis [3,4]. In advance, HIF-1α is reported to
be involved in kinds of progresses of tumorigenesis
including proliferation, angiogenesis, metastasis, and
chemotherapy resistance [5]. Besides, vascular endothe-
lial growth factor (VEGF) is one of the most important
downstream genes of HIF-1α. The critical role of VEGF
in kinds of cancers has indicated that the depression of
VEGF is an important method to treat certain cancers.
Previous studies demonstrated that VEGF promotes
various processes involved in angiogenesis, including
endothelial cell proliferation, adhesion, migration, and
chemotaxis [6]. Angiogenesis is a hallmark of cancer and
has been targeted by various cancer therapies, with a
focused effort on drugs that inhibit VEGF [7]. Advanced
studies on the depression of the expression of HIF-1α
and VEGF would provide better strategy for the treat-
ment of CRC.
The microrna (MiRNA) is a class of single-stranded non-
coding RNA with 18 to 25 nucleotides, and can regulate
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the relevant gene expression at post-transcriptional level
through inhibiting degrading mRNA or protein translation
of target gene [8]. There has been significant evidence
showing that miRNAs regulate as many as more than 60%
of human protein coding genes [9]. MiRNAs exert import-
ant functions in cancer development, cell differentiation,
and regulation of cell cycles and apoptosis of cancer cells
[10]. Nowadays a growing body of evidence indicated that
miRNAs are key regulators that would contribute to the
initiation and development of various types of cancer. In
the development of cancer, normal regulatory mechanisms
are disrupted by altered expression of tumor-suppressive
or oncogenic miRNAs. Therefore identification of differen-
tially expressed miRNAs during human oncogenesis would
produce certain effects in the detection of physiopathologi-
cal mechanisms of cancers. In a study by Kong et al., it
was reported that miR-199a was down-regulated in both
CRC cell lines and tissues [11]. It was concluded that
miR-199a can regulate CAC1 and reacted as a tumor
suppressor in CRC. Besides, a recent study showed
that miR-199a overexpression suppressed the hypoxia-
induced proliferation of non-small cell lung cancer
cells through targeting elevated HIF-1a and blocking
the downstream upregulation of (Pyruvate dehydro-
genase lipoamide kinase isozyme 1) PDK1 without af-
fecting AKT activation [12]. Besides, another study
showed that up-regulation of miR-199a suppressed cell
proliferation, motility and angiogenesis of ectopic stem
cells by targeting the 3′ untranslated region of VEGF
[12]. In this study, we hypothesized that miR-199a
could down-regulated both HIF-1 and VEGF and thus
work as a CRC suppressor. The aim of the present
study was to investigate the functional significance of
miR-199a and to identify the molecular target genes
regulated by miR-199a in CRC cells. Here, we investi-
gated the expression of miR-199a in CRC. Besides, we
assessed the effect of miR-199a on biological behav-
iours including cell proliferation, apoptosis, migration
and invasion of CRC cells.
Methods
Tissue samples
Written informed consents were obtained from all the
patients and all samples were collected according to the
protocols approved by the Clinical Research Ethics
Committee of Guangdong Medical College, Zhanjiang,
Guangdong.
Tissue samples were prepared in a similar manner as
described previously [13]. Briefly, 28 samples (14 tumor
and 14 metastasis tissues from 15 males, 13 females;
59.18 ± 12.34 and 57.53 ± 11.21 years old, respectively) of
CRC tissues were obtained from patients who under-
went surgical resection at Guangdong Medical College,
Zhanjiang, Guangdong 2013 to 2014. Nontumourous
colorectal tissues more than 3 cm away from the tumors
were selected as controls. None of the patients received
preoperative treatment, such as radiation therapy or
chemotherapy.
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the protocol of
manufacturer. RNA concentrations were determined
by spectrophotometer. RNA quality was confirmed
using a NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific, USA).
Quantitative real-time RT-PCR
Stem-loop RT-PCR (TaqMan microRNA assays; Applied
Biosystems, Foster City, CA, USA) was used to quan-
tify miRNAs according to manufacturer’s prtocal. To
normalize the data for quantification of miR-199a,
we used RNU48 as a reference. The ΔΔCt method
was used to calculate the fold-change.
Cell transfection
Exponentially growing cells (1.5 × 105) were seeded in
12-well plates 12 h before transfection and were trans-
fected with 30 nM miR-199a precursor (miR-199a
group) or negative control (control group) using the
X-tremeGENE transfection reagent (Roche Applied
Science, Indianapolis, IN, USA) according to the manufac-
turer’s instructions.
Proliferation assay
Proliferation assay was conducted by the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide
(MTT) method. At 0 to 7 days post-transfection, the
transfection medium in each well was replaced by
100 ml of fresh serum-free medium with 0.5 g/L MTT.
After incubation at 37°C for 4 h, the MTT medium was
removed, and 50 ml of Dimethyl Sulfoxide (DMSO) was
added to each well. After incubation at 37°C for another
10 min, the A570 nm of each sample was measured
using a plate reader.
Apoptosis and cell-cycle analysis by flow cytometry
At 72 h post-transfection, the SW480 cells were har-
vested and re-suspended in phosphate-buffered saline
(PBS) and then fixed in ethanol at −20°C overnight. The
cells were washed with PBS and resuspended in staining
solution (50 μg/ml propidium iodide, 1 mg/ml RNase A
and 0.1% Triton X-100 in PBS). In brief, cells were tryp-
sinized, collected and then stained using the Annexin
V-FITC/PI Apoptosis Detection Kit following the
manufacturer’s instructions. After incubation with Annexin
V-FITC and PI, the apoptotic cells were immediately ana-
lyzed by flow cytometry. Early apoptotic cells were defined
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as the population that was PI negative and Annexin
V-FITC positive, while late apoptotic cells were PI
positive and Annexin V-FITC positive. The cell cycle
detected by stained cells (1 × 105) were analyzed with
an FACScalibur; Becton Dickinson Flow Cytometer (PT.
Madagasi Brosa Inc., Batang Hari, Propinsi Sumatera
Utara, Indonesia).
Western blot
Two groups of SW480 cells (miR-199a and control
groups) were washed with ice-cold PBS for 3 times,
added RIPA lysis buffer, lysed on ice for 30 min,
scrapped off, transferred into EP tube and centrifuged at
4°C, 12000 × g for 30 min. The supernatants were col-
lected and protein concentration was determined using
BCA protein quantitation kit. Each sample with 60 μg
protein was added 1 × SDS sample buffer, and denatured
at 95°C for 5 min. Proteins were separated by 10% SDS-
PAGE electrophoresis and transferred to 0.45 μm NC
membrane. Membrane was blocked with 5% skim milk
for 1 h, and incubated with 1:1000 diluted HIF-1aα and
VEGF antibodies at 4°C overnight. The membrane was
then incubated with 1:1000 diluted β-actin antibodies at
room temperature for 1 h, washed with PBST three
times, and detected with Odyssey system.
Cell migration and invasion assays
SW480 cells was cultured in 25 cm2 culture flask to
approximately 80%-90% density and then seeded into
6-well plates at 2.5 × 105 cells/well. A 6-well plate
was placed in cell culture incubator until cell monolayer
reaches 40%-50% density. The transfected cells were in-
cubated until the cell monolayer reached to 100% density.
The bottom of 6-well plates was scratched with a P200
pipette tip and washed 3 times with PBS to wash off un-
attached cells. The width of scratch was observed at 48 h
using inverted microscope (50-fold). Cell migration assay
was conducted with transwell inserts with 8.0 mm pore
size membrane (24-well format, Corning, New York,
USA). To measure invasion ability of CRC cells, the
previously mentioned inserts were pre-coated with matri-
gel matrix (BD Science, Sparks, MD, USA). The cells
(1 × 105) were re-suspended in serum-free medium and
seeded to the upper chamber. The lower chambers were
filled with complete culture medium containing 10% fetal
calf serum (FBS). After incubation at 37°C for 24 h, the
migrated cells present on the lower side of the membrane
were fixed, stained and counted. Each experiment was
performed in triplicate.
Statistical analysis
Analyses were performed using the statistical package
SPSS 19.0 (ver. 19.0; SPSS Institute Inc. Chicago, USA).
Differences were analyzed with the Student’s t-test
between two groups or with one-way ANOVA among
three groups for the differences of miR-199a expression
between cancer, metastasis and non-tumourous tissues.
Data were expressed as the means ± standard deviation
from at least 3 separate experiments. P values of < 0.05
are considered significant.
Results
MiR-199a down-regulation in CRC and metastasis tissues
MiR-199a expression was detected in 14 CRC, 14 metas-
tasis and adjacent non-neoplastic colorectal tissues nor-
malized to RNU48. As shown in Figure 1, we found that
the expression of miR-199a was distinctly decreased in
colorectal cancer tissues compared with non-neoplastic
lung tissues (mean ± SD: 3.7 ± 0.4 vs. 5.2 ± 0.8, P < 0.05).
In addition, miR-199a expression in metastasis tissue
was lower compared with the control group (mean ± SD:
2.2 ± 0.3 vs. 5.2 ± 0.8, P < 0.01).
The effects of miR-199a overexpression on CRC cell growth
In order to assess the effects of miR-199a on CRC cell
growth, the miR-199a precursor was transfected into
SW480 cells and cell growth at various post-transfection
time points (0 to 7 days) was examined. As showed in
Figure 2A, miR-199a precursor treatment was found to
up-regulate miR-199a expression in SW480 cells. Be-
sides, we found that miR-199a would reduce the cell
growth after treated for more than 3 days (Figure 2B).
The effects of miR-199a overexpression on CRC cell
proliferation
As showed in Figure 3, addition of miR-199a precursor
would up-regulate miR-199a expression in SW480 cells.
In the various post-transfection time points, the CRC
cell proliferation of miR-199a group was significantly
Figure 1 MiR-199a was significantly decreased in CRC tissues. The
mRNA expression of miR-199a was measured by qRT-PCR in CRC,
metastasis and adjacent normal tissue. Graph represents the 2-ΔΔCt
values ± SD, * P < 0.05; ** P < 0.01.
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reduced than the control group (P < 0.05) since the
third day.
MiR-199a transfection on apoptosis rate and cell-cycle of
CRC cell
We further investigated the effect of miR-199a on apop-
tosis of SW480 cells. SW480 cells were transfected with
100 nmol/L of miR-199a precursor mimics for 72 h.
Flow cytometry analysis demonstrated that the percent-
age of the G0/G1, G2/M and S phase (43.2% for G0/G1
phase, 5.4% for G2/M phase and 51.4% for S phase) in
control group. While the percentage of the G0/G1, G2/M
and S phase (60.9% for G0/G1 phase, 8.8% for G2/M
phase and 28.3% for S phase) in the miR-199a group
were not significantly different with the control group
(Figure 4A). To determine whether the SW480 cell
growth regulation was attributed to apoptosis, we per-
formed flow cytometric analysis of SW480 cells after
transfection of miR-199a precursor mimics and the rela-
tive control minics. In miR-199a transfected SW480
Figure 2 Overexpression of miR-199a on CRC cell growth.
(A) Expression of miR-199a was determined in SW480 cells after
miR-199a precursor transfection compared to controls. (B) The cell
number of SW480 cells after miR-199a precursor transfection compared
to controls.
Figure 3 The cell proliferation was determined in SW480 cells
transfected with miR-199a precursor or negative control (Ctrl).
A450 absorption was assayed after transfection for 24 h.
Figure 4 A) The cell cycles of CRC SW480 cells. B) The apoptosis
rate of CRC SW480 cells. SW480 cells were plated and transfected
with negative control or miRNA-199a mimics for 72 h. MiR-199a
induced apoptosis of SW480 Cells. s. Flow cytometry analysis
demonstrated that the percentage of the G0/G1, G2/M and S phase.
The apoptosis rate was detected after transfection and tested
with Annexin-V/PI.
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group, the rates of early and late apoptosis rate are 5.2%
and 0.9%. While the rates in control minics transfected
cells were 4.8% and 1.1%, respectively (Figure 4B). No
significant differences were detected in the apoptosis
rate in both groups (P > 0.05).
MiR-199a reduces migration and invasive phenotypes of
SW480 cells
In the migration assay, we found that the SW480 cells
transfected with miR-199a precursor mimics have a
lower migration rate compared with the control group
(0.77 ± 0.11 versus 1.00 ± 0.14, P < 0.01, Figure 5A). In
the transwell assay for the invasive ability, the invasive
cells per field of view through the porous transwells
were significantly reduced in the miR-199a precursor
mimics transfected cells compared to the control mimics
transfected cells (1.95 ± 0.22 versus 3.34 ± 0.32, P < 0.01,
Figure 5B).
MiR-199a transfection was associated with decreased
HIF-1α and VEGF
We further determined the expression of HIF-1α/VEGF
protein by western blot in CRC cells transfected with
miR-199a precursor or control minics. To investigate
the modification by miR-199a of the key HIF-1α/VEGF
signaling proteins in human CRC cells, the expressions
of HIF-1α and VEGF were determined by western-blot
assay. As shown in Figure 6, miR-199a precursor mimics
treatment was inversely correlated with decreased expres-
sion of HIF-1α and VEGF (Figure 6A and 6B, P < 0.01).
Discussion
Emerging evidence has highlighted the crucial role of
miRNA dysregulation on tumourigenesis of human
CRC. MiRNA dysregulation modified cell proliferation,
confers resistance to apoptosis, and enhances invasive-
ness and metastasis, through repressing the downstream
target genes, and thus is involved in the initiation, pro-
gression, and metastasis of human tumors. In this study,
we found that miR-199a down-regulation was associated
with the CRC and metastasis incidence. Advanced study
showed that miR-199a up-regulation would lead to
decreased CRC proliferation, migration and invasion.
However, no significant association of miR-199a treatment
and apoptosis rate and cell-cycle were detected in this
study. The mechanisms of miR-199a on the development
of CRC showed that the anticarcinogenic effect of miR-
199a might be produced through HIF-1α/VEGF pathway.
The discovery of miRNAs provided a powerful ap-
proach for exploring many complicated cellular bio-
logical functions in the tumorigenesis. In several
published studies, miR-199a has been found to be in low
expression level in kinds of cancers [14-17]. Up-
regulation of miR-199a might be used as tumor repres-
sor for kinds of cancer. In a previous study, Cheng et al.
confirmed that miR-199a could target CD44 via a
Figure 5 MiR-199a inhibited migration and invasion of SW480 cells. Cell migration and invasion ability was analyzed by scratch test and transwell
tests after miR-199a or NC transfection. A: Representative images of scratch test transfected with miR-199a or NC. B: Quantification of the migratory cells
by solubilization of crystal violet. Data represented mean ± SD, P < 0.01.
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miR-199a-binding site in the 3′-UTR. The human miR-
199a was cloned and transfected into ovarian CICs and
the results found that CD44 mRNA and protein expres-
sion was significantly decreased in miR-199a-transfected
ovarian CICs as compared with miR-199a mutant-
transfected and untransfected cells. Cell cycle analysis,
the colony formation assay and the transwell migration
assay indicated that miR-199a significantly affected cell
cycle regulation and suppressed the proliferation and
invasive capacity of ovarian CICs in vitro [18]. Tsukigi M
et al. [19] conducted an independent study and they
reportedshow that re-expression of miR-199a downregu-
lated GSK-3β and suppresses cancer cell growth. The re-
sults demonstrate low miR-199a expression as a feature
of advanced renal cell carcinoma, identify miR-199a as a
negative regulator of GSK-3β, and suggest re-expression
of pre-miR-199a as a new potential treatment of renal
cell carcinoma. For the CRC, decreased miR-199a expres-
sion was detected compared with the controls. Hu et al.
reported that overexpression of miR-199a would result in
reduced colony formation, invasive and migratory cap-
abilities of different human CRC cell lines [20]. Through
the dual luciferase reporter assay, it was also found that
overexpression of miR-199a-5p led to decrease DDR1,
MMP2, N-cadherin and vimentin expression and in-
creased E-cadherin expression through binding to their
3′-UTR sites.
In previous study, the tissue hypoxia induces repro-
gramming of cell metabolism and may result in normal
cell transformation and cancer progression. HIF-1α, the
key transcription factor, plays an important role in CRC
development and progression [21]. VEGF is over-
expressied in CRC cells and plays a critical role in angio-
poiesis and cell proliferation, making it a potential target
for cancer therapy. A recognized cancer suppressor,
phosphatase and tensin homologue (PTEN), has been
reported to be associated with the development of CRC.
In a previous study, PTEN was reported to have a cor-
relation with VEGF expression via HIF-1α, and the
PI3K/mTOR pathways [22]. In a retrospective study, it
evaluated the HIF-1α expression by immunohistochemi-
cal staining and analyzed its association with several
clinicopathological characteristics. It showed a signifi-
cant correlation was also observed between the expres-
sions of HIF-1α and VEGF in liver metastases and
primary CRC [23]. Nagaraju GP et al. reported that
ganetespib could work as a potential anti-cancer agent
and it effected through HIF-1α/VEGF pathway [21]. The
results provided potential eligible drug detection for
the CRC.
MiR-199a has been reported to be a potential inhibitor
of HIF-1α/VEGF pathway. Joshi et al. reported that
miR-199a targets the 3′-UTR of HIF-1α and HIF-2α.
Decreased miR-199a expression in hypoxia increased
HIF levels. Exogenous expression of miR-199a decreased
HIF, cell migration, and metastasis of ovarian cancer
cells [24]. In an in vivo and in vitro study, up-expression
of miR-199a and miR-125b inhibited tumor-induced
angiogenesis associated with the decrease of HIF-1α and
VEGF expression in ovarian cancer cells. Moreover, the
levels of miR-199a and miR-125b were negatively corre-
lated with VEGF mRNA levels in ovarian tissues. We
further showed that direct targets of miR-199a and miR-
125b HER2 and HER3 were functionally relevant. Forced
expression of HER2 and HER3 rescued miR-199a- and
miR-125b-inhibiting angiogenesis responses and Akt/
p70S6K1/HIF-1α pathway [25]. Compared to parental
cells or cells transfected with a control vector, the over-
expression of microRNA-199a in the hepatocellular
carcinoma cell lines stably was showed to reduce cell
proliferation in vitro and in vivo. Advanced study re-
vealed the regulation of miR-199a on 3′-UTR of HIF-1α.
Figure 6 MiR-199a inhibited HIF-1α and VEGF expression in SW480 cells. A: Western blotting analysis of HIF-1α and VEGF protein level. The β-actin was
used as a loading control. B: The expression level of HIF-1α and VEGF in SW480 cells, normalized by β-actin expression, P < 0.01.
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Further investigation confirmed that miR-199a signifi-
cantly reduced the endogenous protein level of HIF-1α
in hypoxia. MiR-199a inhibits cell proliferation in vitro
and in vivo partly through down-regulation of HIF-1α in
human hepatocellular carcinoma [26].
Conclusion
In conclusion, we conducted detailed analyses on the effect
of miR-199a on the CRC cell line. Through the analyses on
the miR-199a on the biological behaviors of CRC cell line,
we found that miR-199a would reduce the proliferation,
migration and invasion. However, overexpression of miR-
199a on the apoptosis rate and cell cycles showed no sig-
nificant results. The potential functionary mechanism of
miR-199a might through HIF-1α/VEGF pathway.
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